Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 46 AL 60

Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track?

Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A.

CNS Neurosci Ther. 2013 Aug;19(8):549-55. doi: 10.1111/cns.12095. Epub 2013 Apr 18.

New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors

Greig NH, Reale M, Tata AM.

Recent Pat CNS Drug Discov. 2013 Aug;8(2):123-41. doi: 10.2174/1574889811308020003.

Targeting ubiquilin-1 in Alzheimer's disease

Takalo M, Haapasalo A, Natunen T, Viswanathan J, Kurkinen KM, Tanzi RE, Soininen H, Hiltunen M.

Expert Opin Ther Targets. 2013 Jul;17(7):795-810. doi: 10.1517/14728222.2013.791284. Epub 2013 Apr 21.

Concentration of donepezil to the cognitive response in Alzheimer disease

Yang YH, Chen CH, Chou MC, Li CH, Liu CK, Chen SH.

J Clin Psychopharmacol. 2013 Jun;33(3):351-5. doi: 10.1097/JCP.0b013e31828b5087.

Development and mechanism of γ-secretase modulators for Alzheimer's disease

Crump CJ, Johnson DS, Li YM.

Biochemistry. 2013 May 14;52(19):3197-216. doi: 10.1021/bi400377p. Epub 2013 May 2.

Targeted drug delivery across the blood brain barrier in Alzheimer's disease

Rocha S.

Curr Pharm Des. 2013;19(37):6635-46. doi: 10.2174/13816128113199990613.

Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease

Jia JY, Zhao QH, Liu Y, Gui YZ, Liu GY, Zhu DY, Yu C, Hong Z.

Acta Pharmacol Sin. 2013 Jul;34(7):976-82. doi: 10.1038/aps.2013.7. Epub 2013 Apr 29.

Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities

Van Dam D, Van Dijck A, Janssen L, De Deyn PP.

Curr Alzheimer Res. 2013 Jun;10(5):449-68. doi: 10.2174/1567205011310050001.

Effectiveness and safety of memantine treatment for Alzheimer's disease

Yang Z, Zhou X, Zhang Q.

J Alzheimers Dis. 2013;36(3):445-58. doi: 10.3233/JAD-130395.

Adherence to cholinesterase inhibitors in Alzheimer's disease: a review

Brady R, Weinman J.

Dement Geriatr Cogn Disord. 2013;35(5-6):351-63. doi: 10.1159/000347140. Epub 2013 Apr 19.

Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

Gauthier S, Robillard A, Cohen S, Black S, Sampalis J, Colizza D, de Takacsy F, Schecter R; EMBRACE investigators.

Curr Med Res Opin. 2013 Aug;29(8):989-1000. doi: 10.1185/03007995.2013.802230. Epub 2013 May 23.

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

Parsons CG, Danysz W, Dekundy A, Pulte I.

Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9.

Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits

Davie BJ, Christopoulos A, Scammells PJ.

ACS Chem Neurosci. 2013 Jul 17;4(7):1026-48. doi: 10.1021/cn400086m. Epub 2013 May 23.

β-Arrestins as potential therapeutic targets for Alzheimer's disease

Jiang T, Yu JT, Tan MS, Zhu XC, Tan L.

Mol Neurobiol. 2013 Dec;48(3):812-8. doi: 10.1007/s12035-013-8469-8. Epub 2013 May 16.

[Nicotinic acetylcholine receptor in Alzheimer's disease]

Abe K.

Nihon Rinsho. 2013 Apr;71(4):743-50.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias